Verseon’s CEO Adityo Prakash discussed AI in pharmaceutical drug discovery with MarkTechPost for its current AI in Healthcare issue. Verseon has created a platform that circumvents the limitations of trial-and-error testing and “AI-first” approaches employed other pharmaceutical companies today.
—
Fremont, Calif.—Verseon’s CEO Adityo Prakash gave his perspective on the use of AI in pharmaceutical drug discovery to MarkTechPost for its current AI in Healthcare issue. Among the items discussed was Verseon’s ability to systematically design and develop precision treatment candidates for major diseases. Verseon has created a platform that circumvents the limitations of trial-and-error testing and “AI-first” approaches employed other pharmaceutical companies today.
“My position is that the companies making the best use of AI will be the ones that couple AI techniques with significant advances in many other scientific arenas to make the discovery of completely new drugs more reliable, robust, and streamlined. Those companies will be the new leaders in the field of pharmaceutical medicine. Verseon plans to be foremost among them,” said Prakash.
Verseon’s integration of fundamental advances in computational chemistry, molecular-physics modeling, and applications of AI allows the company to explore parts of the drug-like chemical space no other method can examine. Whereas other methods are able to look only at compounds similar to previously synthesized and characterized drugs, Verseon is able to predict with high accuracy how molecules that have never before been synthesized will interact with disease-causing targets. The platform also uses the rules of chemistry to generate synthesis instructions for novel drug candidates, saving time and eliminating technical obstacles to producing drug candidates at scale.
For every drug program, Verseon examines a hundred billion or more novel chemotypes to find the most suitable drug candidates. This chemical novelty matters because many compounds among the billion trillion trillion that have not previously been synthesized possess desirable characteristics the existing pharmacopeia does not. According to Prakash, “It’s in this vast unknown ocean of possibilities that truly novel small molecules with unique pharmacological properties can be found.”
Examples of the unique drug candidates Verseon has created include blood thinners to prevent heart attack and stroke with substantially lower risk of uncontrolled bleeding than existing anticoagulant drugs and a new class of oral drug candidates that could someday replace regular injections in the eye to treat the most common form of diabetic vision loss. The company has also launched a multipronged effort to combat cancer, with three programs currently in development. These include novel chemotherapy agents that do not lose effectiveness when cancers become resistant to other chemotherapy agents, an immune-oncology program to circumvent a mechanism that tumors use to evade the immune system, and agents to combat aggressive metastatic cancers. As Verseon advances these and other future programs, the company is in position to positively impact global health.
About Verseon
To advance global health, Verseon International Corporation has created a better, more scalable process for designing and developing new drugs addressing currently untreatable or poorly treated conditions. The company’s drug development platform incorporates fundamental advancements in molecular modeling, directed synthesis, integrated translational research and AI to develop drug compounds that have never before been synthesized—and are virtually impossible to find using conventional methods. Verseon is a clinical-stage company with a growing pipeline that currently includes seven drug programs in the areas of anticoagulation, diabetic retinopathy, hereditary angioedema, oncology, and metabolic disorders.
Contact Info:
Name: Walter Jones
Email: Send Email
Organization: Verseon
Address: 47000 Warm Springs Boulevard, Fremont, CA 94539, United States
Website: https://www.verseon.com
Release ID: 89073685
